Future Aspects of Neuroblastoma Research

Discoveries in the past two decades have been pivotal in unraveling the molecular foundations of neuroblastoma, leading to a refined comprehension of its heterogeneity, clinical classification, identification of novel targets, and impact on patient outcomes. However considerable hurdles remain in improving our existing chemotherapy-based therapies, which have reached toxicity limits and lead to significant long-term morbidity. Single-cell technologies are poised to provide further insights into the cellular phenotypes of neuroblastoma and elucidate the roles played by non-cancerous supporting and immune cells in therapy resistance and tumor recurrence. New pre-clinical model systems will be instrumental in evaluating the rapidly growing field of targeted and immune-based therapies. Furthermore, it’s crucial to broaden international collaborative efforts to evaluate these combination therapies through early and randomized clinical trials.